Senator John McCain has been handed a grim neurological diagnosis. Plus, a new headache treatment is on the market.
State drug agencies face a new and growing threat in gabapentin abuse as the NIH battles through a brain tissue shortage.
Researchers say serotonin levels may be a biomarker of SIDS. Plus, new findings may help develop therapeutics that can better penetrate the blood-brain barrier.
Researchers plan a controversial trial to use stem cells to try and reverse brain death. Plus, protective mutation A673T lends support to the amyloid hypothesis, and the molecule LRP4 may shed light on synaptic imbalances that can lead to epilepsy.
Patients are facing major backlash from insurers refusing to cover the cost of a controversial Duchenne muscular dystrophy drug while the National Academies of Sciences are recommending steps to prevent dementia.
A large genomic study has identified 5 genes related to insomnia, plus hear from the DAWN trial investigators on the impact their data might have on the future of stroke treatment.
In a first, the FDA has requested the removal of an opioid medication from the market. Plus, is snake venom the latest antiplatelet agent?
New research suggests that ketamine may do more harm than good when it comes to preventing delirium, plus is an old, cheap, generic drug about to be repurposed for another neurologic disorder?
What US hospitals can learn from the ransomware attack on the UK health care system, plus the latest hurdle for Sarepta's DMD drugs.
A new treatment for ALS gets a green light from the FDA as the NIH prepares to take a deep dive into chronic fatigue syndrome.
A third of the population has experienced "mini" stroke, but most don't know how to handle it. Plus, catch up on the latest drug price controversy for rare-disease drugs.
Did you miss out on AAN? Catch up on the latest science with Neurology Advisor's live coverage, plus learn about the latest FDA approval.
A report ties over 4000 children with birth defects to a popular epilepsy drug, while the FDA issues a stern warning about the use of codeine and tramadol in children.
The latest studies suggest that silencing the SCA2 gene may help reduce symptoms of ALS and deep brain stimulation may quell tics associated with Tourette's syndrome.
Teva's Huntington's chorea drug names a competitive price as other drug makers pursue phase 3 studies in glioblastoma and depression despite disappointing data.
Pricing criticism strikes Roche's Ocrevus as the nominee for FDA commissioner comes under fire for potential conflicts of interest.
The CDC says we should be paying more attention to fall-related concussion prevention in the elderly while one of the NFL's own heads to Harvard for a neurosurgery residency.
Marathon sells off its controversial DMD drug as the FDA stands to double its fees for the drug approval process under the new Trump budget.
The Obamacare replacement is here, and opposition is growing among medical groups. Plus, alternative medicine is having its moment at some major hospitals, while telemedicine proves to be a bust for health care costs.
While Genentech rolls the dice on a second phase 3 trial for its anti-amyloid agent, a new biotech startup is tapping CRISPR technology to restore dystrophin production in Duchenne muscular dystrophy.
Follow timely coverage of the International Stroke Conference right here on Neurology Advisor.
Just days after it received FDA approval, Marathon's Emflaza is under fire from critics who claim the price of the Duchenne muscular dystrophy drug is exorbitant.
Still feeling aftershocks from its failed Alzheimer's trial, Eli Lilly announced more layoffs while Biogen faces an investigation into its payment programs for its top MS drugs.
Traumatic brain injury continues to make major headlines as a new crop of lawsuits hit the docket ahead of Super Bowl LI. Plus, are we too quick to rush to in-human trials? The authors of an op-ed in Nature think so.
One US town tries to take Big Pharma to court over the opioid crisis while the FDA continues to approve new, abuse-deterrent opioids. Plus, the first patient with refractory mesial temporal lobe epilepsy has undergone laser ablation surgery as part of the SLATE trial.
The medical community questions whether mobile stroke units are sustainable, new research further links concussions with Alzheimer's disease, and a new trial examines the effects of fasting on MS.
Happy New Year! Reflect on some of 2016's greatest neurological advances and look forward as institutions like the NIH take on a focused effort to explore new drugs for rare disease, the developing brain, and more.
The FDA has delayed the decision on ocrelizumab after manufacturing issues arise, while it gives the thumbs up to an investigational treatment for complex regional pain syndrome.
The NCAA honored the man and ALS patient behind the viral ALS Ice Bucket Challenge, while the UK approved mitochondrial replacement reproductive assistance and Bristol-Myers Squibb faces a $20 million fine for promoting off-label uses of its antipsychotic Abilify.
The Handoff: Your Week in Neurology News - 12/8/16
Neurology Advisor Articles
- Minocycline May Slow Progression From Clinically Isolated Syndrome to Multiple Sclerosis
- Brain Inflammation Observed in Obsessive-Compulsive Disorder
- Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease
- Growing Old Without Alzheimer's Pathology: What's the Secret?
- Traumatic Brain Injury May Increase Later Risk of Dementia